Wei Xinkang announced that Inner Mongolia Baiyi Pharmaceutical, a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for injectable multivitamins approved and issued by the State Drug Administration. The registration classification is classified as a category 4 chemicals, which is deemed to have passed the consistency evaluation. This medicine is suitable for adults and children aged 11 and over who need vitamin supplementation through injections. In 2025, terminal sales of this drug in public medical institutions in China were 1,601 billion yuan. As of the end of July 2026, a total R&D investment of 11.313,900 yuan was made.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.